Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:37:00.818Z.
Consensus retrieved: 2026-10-06T11:26:34.005Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:37:00.818Z.
Quote observation: 2026-10-06T16:35:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 31946573a42b73cd13b381604bc2f467f5098c78190e00cee0d2639f3054c777
Forward PE Ratio (N/A) = Dated Quote Price ($12.80) / Consensus Forward EPS ($-4.14)
FORWARD PE RATIO
N/A
4D Molecular Therapeutics, Inc.
Market Cap
$669.14M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $669.14M | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $669.77M | N/A |
| Helus Pharma Inc. (HELP)vs › | $677.18M | N/A |
| Annexon, Inc. (ANNX)vs › | $677.49M | N/A |
| OmniAb, Inc. (OABI)vs › | $656.00M | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $685.38M | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $690.15M | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $634.18M | N/A |
| Climb Bio, Inc. (CLYM)vs › | $630.47M | N/A |
| Prime Medicine, Inc. (PRME)vs › | $630.35M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $12.80, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-4.14 | $-4.28 – $-3.94 | 7 | n/m |
| 2027-12-31 | $-4.09 | $-4.34 – $-3.50 | 7 | n/m |
| 2028-12-31 | $-3.76 | $-4.71 – $-2.92 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
